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Abstract
We report here the speciﬁc interaction between several members of the human galectin family with
the three developmental stages of several genetic lineages of the protozoan parasite Trypanosoma
cruzi. We provide data of speciﬁc and differential binding of human galectin (gal)-1, -3, -4, -7 and -8 to
14 strains of T. cruzi that belong to the six genetic lineages representing the genetic diversity of the
parasite. It is shown that galectins preferentially bind forms present in the host, trypomastigotes and
amastigotes, compared with the non-infective epimastigote present on the intestinal tract of the vec-
tor, reﬂecting the changes on glycosylation that occur during the metacyclogenesis and amastigo-
genesis process. Also, it is evidenced that galectin binding to the parasites promotes binding to the
host cells and higher infection rates. In addition, evidence is provided indicating that the intracellular
amastigotes may take over the cytosolic pool of some galectins when released to the extracellular
medium. Finally, by applying unweighted pair group method analysis to the galectin-binding proﬁle
to either cell-derived trypomastigotes or amastigotes, we show that the differential-binding proﬁle by
the host galectins to the six lineages resembles the clustering based in genetic data. Therefore, the
differential-binding proﬁle for the six lineages could have implications in the immunopathology of
Chagas’ disease, affecting the complex network of immune responses on which galectins mediate,
thus providing linkage clues to the notion that different lineages may be related to different clinical
forms of the disease.
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Introduction
Trypanosoma cruzi is the causative agent of Chagas’ disease, a chronic
disorder endemic in Latin America (World 2010). The disease exhibits
diverse clinical manifestations, starting with a short acute phase with
variable parasitemia, followed by an indeterminate phase when no
signiﬁcant clinical symptoms (Coura and Borges-Pereira 2010;
Rassi et al. 2010). After a few months, the chronic stage develops in
∼30–35% of infected, causing mainly cardiac or digestive alterations.
However, the host factors responsible of triggering immune mechan-
isms during disease progression still remain undetermined. Trypano-
soma cruzi has a digenetic life cycle with at least three different life
stages: epimastigotes and metacyclic trypomastigotes in the insect vec-
tors and trypomastigotes and intracellular amastigotes in the mamma-
lian hosts (de Souza 1984). The invasion of the human host mainly
occurs by entrance through damaged skin or intact mucosa of meta-
cyclic trypomastigotes released with the feces of infected insect vectors
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after their blood meal. The trypomastigotes are able to infect a wide
variety of host cells (de Souza 1984), where they transform into pro-
liferating intracellular amastigotes. The amastigotes differentiate into
bloodstream trypomastigotes that disseminate, before going through
another intracellular cycle or taken up by the insect closing the life
cycle. In order to adapt and survive into these different environments,
the life forms present different plasma membrane composition, the
main changes observed in the glycosylation proﬁle of each biological
form (de Lederkremer and Agusti 2009).
Trypanosoma cruzi is subdivided in six discrete typing units
(DTUs) with differential geographical, transmission cycles, vector
and host distribution (Macedo et al. 2004; Aquilino et al. 2012) and
has been suggested that this polymorphism could be related to the clin-
ical manifestations of the disease. However, little is known about the
host molecules involved on the differential parasite recognition. Most
of the pathogen-associated molecular patterns described so far in
T. cruzi are glycosylated (such as GPI-linked, mucins and trans-
sialidases) and control activation of the innate immune system and ini-
tiation of the acquired host immune response in the vertebrate host
(Almeida et al. 2000; Procopio et al. 2002; Previato et al. 2004;
Nogueira et al. 2007; Alcaide et al. 2010). Therefore, characterization
of the interaction between parasite glycans and their host’s putative
receptors is of outstanding relevance. Among the wide array of host
receptors, galectins have attracted attention over the last years due
to the large number of immune functions ascribed to them. Galectins
are a conserved family of animal lectins with preserved structure and
calcium-independent afﬁnity for β-galactosides (Vasta 2012), yet exhi-
biting different ﬁne speciﬁcity and afﬁnity. They are widely expressed
on diverse cell types, from immune-privileged tissues to epithelial cells
of intestinal tract. However, each one exhibits a restricted tissue distri-
bution (Nio-Kobayashi et al. 2009) and shows a pleiotropic range of
effects mainly related to inﬂammatory processes. Collectively, the ﬁnal
interplay of the galectin signaling network will be the cumulative re-
sult of each individual member interacting with its cognate ligands. It
has become increasingly clear that different regulatory immune cir-
cuits can be associated to multiple activation of immune pathways
triggered by PRRs (Dam and Brewer 2010a, 2010b; Amit et al.
2011; Chevrier et al. 2011). Hence, having several members of the
galectin family to differentially scrutiny and mediate pathogen recog-
nition constitutes a powerful mechanism to ﬁne tune the subsequent
immune response.
There have been reports suggesting involvement of galectins in
T. cruzi infection, such as changes in expression of galectins and/or
its ligands upon infection (Zuniga, Gruppi, et al. 2001; Zuniga,
Rabinovich, et al. 2001; Vray et al. 2004; Silva-Monteiro et al.
2007), changes in subcellular location of gal-3 (Machado et al. 2014;
Reignault et al. 2014). It has also been shown that gal-3 is able to pro-
mote trypomastigotes adhesion to extracellular matrix components
(Moody et al. 2000; Kleshchenko et al. 2004). However, the relevance
of galectins in T. cruzi infection is still far from being resolved.
Here we report the ﬁrst systematic study of the binding of several
members of the human galectin family towards three life forms of
T. cruzi. Galectins present a higher afﬁnity to the biological forms
found in the vertebrate host, compared with the non-infective forms
present in the insect vector. Secondly, by using unweighted pair-group
method analysis of galectin-binding proﬁle to epimastigotes and
cell-derived trypomastigotes (CTT) of the six different DTUs, the 14
T. cruzi strains analyzed could be arranged in ﬁve clusters that closely
resembled the grouping based solely on genomic data. In addition,
several galectin ligands on the surface of the parasite had been
identiﬁed.
Materials and Methods
Cells and parasites
Vero (green monkey kidney epithelial cells, ATCCCCL-81), LLC-MK2
(rhesus monkey, kidney epithelial cells, ATCCCCL-7), CaCo-2 (human
colorectal adenocarcinoma cells, ATCC HTB-37) and THP-1 (human
monocytes, ATCC TIB-202) cells were grown in RPMI complete me-
dium containing 5% FCS, 2 mM L-glutamine, penicillin (100 U/mL)
and streptomycin (100 μg/mL) (Gibco, Grand Island, NY) at 37°C in
an atmosphere containing 5% CO2. The mouse cardiac cell line HL-1
(Claycomb et al. 1998) was obtained and grown according to Dr. Clay-
comb (Department of Biochemistry & Molecular Biology, School of
Medicine, Louisiana State University).
All parasite strains listed in Table I were genotyped as described in
Zingales et al. (2012) and DTU assigned according to the new consen-
sus on nomenclature on genetic lineages of T. cruzi (Zingales et al.
2009). Epimastigotes life forms were continuously cultured in liver in-
fusion tryptose medium supplemented with 5% fetal calf serum, and
0.01% hemin as described previously (Alcina and Fresno 1988). CTT
were obtained from the supernatant of infected Vero cells at 4–6 days
post-infection and isolated by differential centrifugation, and recov-
ered from the supernatant after 2 h incubation at 37°C, this procedure
was repeated once to reduce the proportion of intermediate forms and
amastigotes. The ﬁnal population was never <95% highly motile
trypomastigotes.
Amastigotes were obtained from 3 to 4 days infected Vero cells
after lysis, either by Percoll discontinuous density gradient as de-
scribed (Gamarro et al. 1985) or by anion-exchange chromatography
(Marques et al. 2011). Microscopic examination indicated that 98 or
95%, respectively, of the population was homogeneous. No differ-
ences in the binding proﬁle were detected. Given the highly consistent
yield of the Percoll gradient method, it was the preferred method.
Galectins
Expression plasmid pQE60 containing the human gal-1 sequence was
kindly provided by Dr. Elena Moisevaa (Leicester Warwick Medical
School, UK). The protein was puriﬁed as described previously
(Andersen et al. 2003). Expression plasmids for human gal-3 and -4
were provided by Dr. Hakon Lefﬂer (Lund University, Sweden)
(Patnaik et al. 2006). Expression plasmid pGEX containing the
human gal-7 sequence was provided by Dr. Thierry Magnaldo (Insti-
tut Gustave Roussy, France) (Magnaldo et al. 1995). Four expression
Table I. Strains of T. cruzi used in this work
Strain DTU Origin Host/vector
Silvio/X10 c1 I Belem, Brazil Homo sapiens
Dm28c I Carabobo, Venezuela Didelphis marsupialis
Esmeraldo c3 II Bahia, Brazil Homo sapiens
Y II Sao Paulo, Brazil Homo sapiens
Tu18 c2 II Tupiza, Bolivia Triatoma infestans
Cm17 III Carimaga, Colombia Dasyprocta fugilinosa
M6241 c6 III Para, Brazil Homo sapiens
Can III c11 IV Para, Brazil Homo sapiens
10R26 IV Santa Cruz, Bolivia Aotus sp.
Bug2148 c11 V Rio Grande do Sul, Brazil Triatoma infestans
Sc43 c1 V Santa Cruz, Bolivia Triatoma infestans
Tula c2 VI Tulahuen, Chile Homo sapiens
VFRA c1 VI Francia, Chile Triatoma infestans
CL-Brener VI Rio Grande do Sul, Brazil Triatoma infestans
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plasmids pGEX4T2 containing the human gal-8 sequence and the
mutant gal-8 R69H, gal-8 R233H and gal-8 R69H/R233H sequences
were provided by Dr. Nozomu Nishi (Kagawa University, Japan)
(Nishi et al. 2003). All human recombinant galectins were expressed
and puriﬁed from bacterial pellets as described in the original manu-
scripts and freed of LPS (Lipopolysaccharide) by passage on a
polymixin-Sepharose™ column as described by the manufacturer.
Brieﬂy, bacteria cultures were incubated with 1 mM isopropyl-1-
thiogalactopyranoside for 3 h at 37°C to induce recombinant protein
production. Bacteria were pelleted, suspended in phosphate-buffered
saline 4 mM EDTA, 2 mM β-mercaptoethanol, 10 mM lactose (PBS-
MELac) together with a protease inhibitor cocktail. After sonicating,
bacteria were centrifuged to obtain the soluble fraction. Recombinant
galectins present in this fraction were puriﬁed by afﬁnity chromato-
graph on α-lactose-agarose and eluted with lactose 0.1 M and dia-
lyzed against a buffer containing 0.1 mM β-mercaptoethanol and
10 μM lactose. Once puriﬁed, each galectin was kept at −20°C after
freeze-drying solutions at concentrations >10 μM, in such way galec-
tins were stable for a longer time avoiding proteolysis. Before each ex-
periment, the integrity and purity of each galectin was assessed by
SDS–PAGE and silver staining, and their sugar-binding capacity was
periodically tested (Figure 2 shows a representative silver-stained gel of
puriﬁed recombinant human galectins as used on this manuscript).
Alexa-488-conjugated galectins were prepared by labelling with
Alexa Fluor 488 Microscale Protein Labelling Kit (Life Technologies)
following manufacturer guidelines.
Truncated gal-3 was obtained as described before (Kopitz et al.
2001).
Adhesion and infection assays of T. cruzi to host cells
To study parasite-cell adhesion, THP-1 and LLC-MK2 were used.
T. cruzi CTT were labelled with the ﬂuorescent dye CFSE according
to manufacturer’s instructions (carboxyﬂuorescein diacetate, succini-
midyl ester, Life Technologies). THP-1 cells (106 cells/assay) were in-
cubated with CFSE-labeled parasites in complete RPMI medium
(cell : parasite ratio 1 : 3) for 15 min at 4°C to prevent parasite intern-
alization with or without recombinant galectins. Then, cells were ﬁxed
in 1% paraformaldehyde in PBS. Samples were analyzed by ﬂow cyto-
metry using a FACScalibur ﬂow cytometer (BD Biosciences). Fluores-
cence associated to mammalian cell gating was quantiﬁed as an
indication of cell-attached parasites. To study adhesion of T. cruzi to
LLC-MK2 cell line, cells were cultured in microtiter plate wells and
CTTwere added to each cell in a 1 : 10 cell : parasite ratio, in the pres-
ence or absence of recombinant galectins (0.2–2 µM) at 4°C for
15 min. After PBS washing, the number of parasites attached to the
cells was directly counted in not <10 representative ﬁelds.
Vero or LLC-MK2 cells growing on glass coverslips at 25% con-
ﬂuency in 24-well plates were used for infection assays. Cell-derived try-
pomastigotes were added at an infection index of 10 for 4 h at 37°C, in
the presence or absence of indicated galectins. The cells were washed
three times to remove unattached parasites and kept at 37°C.
At indicated times, cells were washed twice with PBS, ﬁxed with
Bouin´s ﬁxative solution and stained in Giemsa solution. The number
of infected cells and number of intracellular amastigotes per cell were
quantiﬁed counting at least 150 cells in three independent slides by
two different observers.
Flow cytometry assays
Parasites were incubated with Alexa-488-labeled galectins (2 μM) for
15 min at 4°C. Unbound galectins were removed by washing three
times with PBS, and parasites were then ﬁxed in 1% paraformalde-
hyde for 20 min at 4°C. Relative ﬂuorescence intensity was measured
on a FACScalibur ﬂow cytometer (BD Biosciences) and data were ana-
lyzed using FlowJo analysis software (Tree Star).
Identiﬁcation of T. cruzi galectin ligands
To prepare galectin immobilized columns, 5–10 mg of gal-3 and -4 (puri-
ﬁed as previously described) were covalently coupled to HiTrap
NHS-activated columns according to manufacturer’s instructions
(Amersham Biosciences), including 5 mM lactose in the coupling buffer.
Gal-7-GST and gal-8-GSTwere coupled to glutation-Sepharose columns.
Membrane proteins of CTT (Y strain) were obtained by labeling live
parasites with Sulfo-NHS-SS-Biotin, lysed in buffer B (0.2 M NaCl,
20 mM Tris–HCl, 0.1% CHAPS and protease inhibitors cocktail).
The solubilized cell surface biotinylated proteins were puriﬁed by chro-
matography on a Neutravidin column (Pierce) and eluted with DTT
50 mM. The eluted fraction was applied to columns containing the im-
mobilized galectins. Columnswere extensively washedwith buffer B and
buffer B plus 0.5 MNaCl, and then speciﬁcally elutedwith buffer B plus
100 mM lactose. The elutedmaterial was resolved by SDS–PAGE, trans-
ferred to nitrocellulose ﬁlters and probed with biotinylated galectins.
Identical nitrocellulose membrane lanes were cut into 10 slices, re-
duced with dithiothreitol, alkylated with iodoacetamide and digested
overnight with trypsin in a 1 : 40 ratio. Peptides released were acidiﬁed
with triﬂuoroacetic acid (TFA, ﬁnal 0.1%), dried and redissolved in 5 μL
TFA%andacetonitrile 33%. 2,5-Dihydroxybezoic acid 0.5 μLwas used
as matrix and mixed with 0.5 μL of peptide sample on an Anchor-chip
(Bruker) and air dried. The spectra obtained were used forMASCOT in-
house identiﬁcation searches against the TryTrypDB T. cruzi protein
database (Tcruzi_AnnotatedProteins-v7.0, http://TryTrypDB.org). The
T. cruzi surface mucin AgC10 was identiﬁed among the galectin ligands
by using a speciﬁc monoclonal antibody previously described by our
laboratory (Alcaide and Fresno 2004a, 2004b).
Fig. 1. Puriﬁed galectins are shown after SDS–PAGE. Samples of each puriﬁed
recombinant galectin (between 1 and 3 μg) were separated by SDS–PAGE in a
12% gel and silver stained.
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Confocal immunoﬂuorescence microscopy
To study the subcellular location of endogenous galectins in infected
cells, Vero cells were grown on cover slips to 25–30% conﬂuence and
then infected at an infection index (parasite : cell) of 10 with trypo-
mastigotes, strain Y (DTU II), during 4 h at 37°C, after which free
parasites were removed by washing three times with medium before
incubate them at 37°C in an atmosphere containing 5% CO2. After
3 days, the cells were ﬁxed with 1% paraformaldehyde–0.5% glutar-
aldehyde in buffer sodium cacodylate 50 mM, pH 7.1, 70 mMNaCl,
0.1% saponin; washed three times with PBS–0.2% BSA, incubated
with anti-galectin antibody and subsequently with Alexa-488-
conjugated secondary antibody before images were acquired using
Confocal LSM510 META microscope (Zeiss).
Unweighted pair-group method with arithmetic
mean analysis
The clustering was done using Pearson coefﬁcient comparing the me-
dian ﬂuorescence index (MFI) of each DTU when tested against ﬂuor-
escent conjugates of recombinant gal-1, -3, -4, -7 and -8 by using
DendroUPGMA (Garcia-Vallve et al. 1999).
Results
Galectins bind to T. cruzi
First, we screened the binding of highly puriﬁed recombinant human
galectins conjugated to Alexa-488 by ﬂow cytometry to live
epimastigotes, amastigotes and CTT. The purity of the recombinant
galectins employed in the study was assessed by silver-stained SDS–
PAGE gel (Figure 1). Individual life forms of T. cruzi were analyzed
separately. Figure 2A shows a representative ﬂow cytometry histogram
obtained for the Y strain (DTU TcII) in which a differential-binding
proﬁle is observed. There was a higher afﬁnity (in terms of higher
MFI) to the forms present in the host, i.e., CTT and amastigotes,
than to the non-infective in vitro cultured epimastigotes to which
only gal-7 showed a binding clearly distinctive from negative controls.
Gal-7 and -8 showed the highest afﬁnity when trypomastigotes
were tested, whereas gal-1 and -4 were shown to bind amastigotes
(Figure 2B) in a clear indication of different glycan exposition on the
different life forms, evidencing substantial differences in the speciﬁcity
for each galectin. We did not ﬁnd any quantitative difference between
trypomastigotes obtained by metacyclogenesis or CTT (not shown),
suggesting that the change in the surface exposed glycans is inherent
to the life form and not to the differentiation strategy used to generate
them. The binding to CTT was saturable, reaching a plateau at galec-
tin concentrations close to 20 μM (Figure 2C) similar feature was
found for amastigotes and epimastigotes (not shown).
As galectins are soluble proteins located in the cytosol, it is reason-
able to propose that the intracellular pool might bind to amastigotes
exposing galactosides on their surface. In order to test this, puriﬁed
extracellular amastigotes from disrupted-cell supernatants were gal-
actose washed in order to remove any host galectin bound. Under
those conditions, the binding of galectins to parasites was signiﬁcantly
Fig. 2. Human recombinant galectin binding to T. cruzi (strain Y, DTU II) is speciﬁc for different biological stages. Alexa488-labeled recombinant human galectins
were incubated with three parasite life cycle stages at 4°C and galectin binding was quantiﬁed by ﬂow cytometry. (A) Alexa-488-galectins were able to bind T. cruzi,
and the afﬁnity of galectinswas higher for the infective forms of the parasites under the same experimental conditions. Parasites incubatedwith galectins are shown
in solid black, unlabeled negative controls in white. The insets show a representative micrograph of the parasite population employed for each analysis. (B) Mean of
ﬂuorescence index (MFI) of galectins (5 μM) binding to the three life forms. Median ± SD of ﬁve independent experiments is shown. (C) MFI of Alexa-488-labeled
recombinant human gal-1, -3, -7 and -8 bound to CTT vs. galectin concentration. The median ± SD of ﬁve different experiments is shown.
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increased for gal-1, -3 and -7 (P < 0.01, Figure 3A). This is a clear in-
dication that amastigotes are recruiting intracellular galectin (or any
other galactoside-binding protein) from the infected host cells cytosol-
ic pool. No signiﬁcant difference was observed regarding gal-4 and -8.
In contrast, when CTT were subjected to the galactose wash; no in-
crease in theMFI was foundwhen comparedwith control non-washed
trypomastigotes (Figure 3A), suggesting either they are not recruiting
intracellular galectin or the bound proteins are released/processed
shortly after being exposed to the extracellular milieu. Another alter-
native is that trans-sialidase action makes any exposed galactose resi-
due, cryptic for the galectins.
The protein content obtained after galactose washing of isolated
intracellular amastigotes was subjected to SDS separation and western
blot to detect host galectins by using speciﬁc antibodies or streptavi-
din–HRP to detect biotinylated-gal-7 (Figure 3B). As expected,
when sucrose or mannose was used instead of galactose, galectins
were not released from amastigotes, and it did not affect galectin bind-
ing observed by FACs (not shown).
An alternative explanation to the “coating” with endogenous ga-
lectins as responsible for the diminished binding of exogenous galec-
tins would be that the recently released amastigotes do not expose the
galectin ligands and are unmasked or exposed immediately after being
released in the media.
In order to test this hypothesis, we set up in vitro infections of
LLC-MK2 or Vero cells and after 4/5 days the cells were processed
for immunoﬂuorescence to examine the pattern of endogenous galectin
distribution. Interestingly, non-infected cells expressed a uniform cyto-
solic staining pattern for gal-1 and -3 (Figure 4D and E, arrow head), in
clear contrast to infected cells where galectin expression was accumu-
lated on the cell surface of intracellular amastigotes (Figure 4A and B
arrows), conﬁrming that intracellular amastigotes are coated by host en-
dogenous galectins. The possibility of a cross-reacting endogenous
parasite protein homologous to host galectin was ruled out by ﬂow
cytometry (as shown in the controls in Figure 3A) and reports in the lit-
erature showing no speciﬁc cross-reactivity of anti-gal antibodies
against T. cruzi antigens (Giordanengo et al. 2001).
Galectin binding to parasites is carbohydrate
recognition domain dependent
Our data showed that the binding of galectins to T. cruziwas inhibited
by lactose, but not sucrose, suggesting that the lactose-binding domain
is involved in the parasite–protein interaction. To conﬁrm that the
binding of the human galectins to the parasites was carbohydrate rec-
ognition domain (CRD) mediated, we next carried out the binding as-
says in the presence and absence of speciﬁc inhibitory ligands of
galectins. Galectin binding was completely inhibited by lactose at
50 mM (Figure 5A) or thiodigalactoside at 10 mM, indicating that
the CRD was involved in the recognition to the sites exposed on the
surface of the parasites. However, we failed to inhibit galectin binding
when β-galactosidase-treated parasites were used, perhaps as a result
of an incomplete access of β-galactosidase to the ligands due to steric
hindrance from the dense mucin layers or/and to high protein turnover
rate found in T. cruzi.
Unambiguous evidence supporting the implication of the CRD
for the tandem-repeat gal-8 was obtained by using the recombinant
human protein carrying punctual mutations (gal-8R69, gal-8R233
and gal-8R69R233, resulting in a non-functional N-, C terminal
and both N- and C-terminal CRDs, respectively) that abolished
the binding to their natural ligands (Nishi et al. 2006). Gal-8R69
and gal-8R233 presented reduced binding to CTT and the null
double mutant showed an absolute lack of binding, conﬁrming
that the CRD of gal-8 is directly involved in the binding to parasite
ligands.
Gal-3 is the only one member of the chimera-type galectin group,
constituted by a CRD at the C-terminus and a collagen-like domain at
the N terminus that could bind T. cruzi in a CRD-independent man-
ner. In order to determine which domain of gal-3 is responsible for the
interaction with T. cruzi, we studied the binding properties of a trun-
cated gal-3 constituted only by the C-terminus domain including the
CRD after releasing the collagenous domain by collagenase treatment
(Kopitz et al. 2001). As shown in Figure 5C, removal of the collagen-
like N-terminal domain does not affect the binding to trypomastigotes
and amastigotes, indicating that the recognition and binding of gal-3
to the parasite is also CRD mediated.
Galectin binding promotes adhesion to host cells
We next tried to address the functional relevance of the galectin-
trypomastigote interaction on parasite adhesion and/or infection to
host cells. To evaluate this, we next performed in vitro adhesion and
infection assays using several cell lines as models.
Parasite adhesion to THP-1 cells in the presence of recombinant
galectins was quantiﬁed by using a cell cytometry approach in
which the gating of free CFSE-labeled live CTT (strain Y) can be easily
separated from unlabeled THP-1 cells according to their respective
forward and size scatter values. Therefore, any increase in ﬂuorescence
in the cell’s gate is proportional to the number of CFSE-labeled
Fig. 3. Amastigotes and CTT bind host galectins. (A) Amastigotes or
cell-derived trypomastigotes were washed with lactose or sucrose as
described in Materials and Methods before being submitted to ﬂow
cytometry analysis of galectin binding. The median ± SD of three different
experiments is shown. Asterisk indicates signiﬁcant at P < 0.05. (B) Wash
media from amastigotes recovered by centrifugation and ﬁltration on
0.22 μM was resolved by SDS–PAGE and WB with speciﬁc anti-galectin
antibodies (for gal-1 and -3) or streptavidin–HRP for biotinylated gal-7.
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Fig. 5.Galectin binding to trypomastigotes ismediated by the CRD. (A) Negative controls are in solid gray, thin black line refers to parasites after incubationwith FITC
galectins, 2 μM, for 15 min at 4°C. Parasite-associated ﬂuorescencewas quantiﬁed by ﬂow cytometry. In the case of gal-7, the thicker black line (—) corresponds to a
galectin concentration of 20 μM, and the thin line (−) to 2 μM. (B) Metacyclic trypomastigotes were incubated with FITC-labeled gal-8, and with the FITC-labeled
mutants R69, R233 and R69R233 for 15 min at 16°C. The mean of ﬂuoresce intensity was measured by ﬂow cytometry. All the mutants showed a reduced
binding capacity to T. cruzi. (C) Flow cytometry analysis of truncated gal-3 binding to trypomastigotes of T. cruzi strain Y. Negative control (no gal-3, white),
full-length gal-3 (gray trace), truncated C-terminal CRD of gal-3 (black trace).
Fig. 4. Intracellular amastigotes bind intracellular pool of galectins. LLC-MK2 cells (A, C and D) or Vero (B, E and F) growing onto glass coverslips were infected as
described. After 4 days p.i., the cells were processed for immunoﬂuorescence and stained with anti-gal-1, -3 and -7 or just secondary antibody.
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parasites that have been attached to those cells. Mixtures of parasites
and cells in the presence or absence of galectins were submitted to ana-
lysis. We limited the analysis time to 15 min in order to look just for
adhesion, and the temperature to <16°C to keep parasites live but
blocking endocytosis of galectins, limiting protease activity. A positive
correlation between the afﬁnity shown by individual galectins and
their ability to promote parasite adhesion to host cells was observed
(Figure 6A). Thus, gal-3, -7 and -8, the galectins that showed a higher
afﬁnity towards parasite infective forms, were those that promoted
parasite adhesion to THP-1 cells, whereas, gal-1 and -4, with lower
afﬁnity towards trypomastigotes (strain Y), did not increase parasite
adhesion to THP-1 cells compared with control (no exogenous galec-
tin). Similar results were obtained with other different strains tested
(data not shown).
Like the galectin binding to isolated cells, the galectin-mediated
adhesion of parasite to host cells was shown to be dependent on the
CRD as it was abolished by speciﬁc haptens, such as lactose, or by
mutation of both CRDs found in gal-8 (Figure 6B).
As monomeric gal-1 and -7 exhibited concentration-dependent
oligomerization affecting their valency, we decided to test the effect
of such functional aggregation concentration dependent on the bind-
ing. Thus, two concentrations of gal-1 and -7 were tested; 0.2 μM
(mainly monomeric) and 2 μM (mainly dimeric and/or higher oligo-
mers). The data shown in Figure 6C suggest that cell-binding promot-
ing activity of this galectin relies on its multivalent properties acting as
a molecular bridge between parasites and host cells.
Similar assays were carried out with several adherent cell lines to
mimic the physiological environment found in vivo, where T. cruzi
infects epithelial cells, showing a broadly similar pattern of galectin-
induced adhesion (Figure 6D).
To further investigate the relevance of galectin–T. cruzi interaction,
a new set of experiments was conducted to deﬁne whether the
observed galectin-mediated adhesion to host cells translates into high-
er infection rates. Data shown in Figure 7 support that idea, as in the
presence of galectins, concomitant with an increased binding to the
host cells, there is an increased infective ability evidenced by both
Fig. 6. Recombinant human galectins promote parasite adhesion to host cells. (A) CTT (strain Y) were labeled with CFSE, and incubated with non-labeled cells.
Parasites and cells were resolved by ﬂow cytometry due to their different size, and the ﬂuorescence intensity associated to the cell gate (THP-1) was quantiﬁed.
Almost 100% of the parasites presented high ﬂuorescence intensity, and only 6% of the cells showed ﬂuorescence intensity when incubated with parasites in
the absence of rGals. (B) Aliquots of gal-8 was added to the mixture of cells and parasites for 10 min at 16°C, and the rate of positive cells increased to 43.9% of
the total. This binding was abolished in the presence of lactose 50 mM, or when gal-8 R69, R233 and R69R233 were used instead of the wild-type galectin. (C) Mean
ﬂuorescence intensity is shown using the same approach with gal-1, -3, -4, -7 and -8, at 0.2 and 2 μM, in the presence and absence of lactose. Representative results
from two independent experiments performed is shown. (D) CTT (strain Y, DTU II) were incubated with an LLC-MK2, CaCo and HL-1 cells monolayer for 15 min at
16°C in the presence or absence of 2 μM recombinant galectin, after extensive washing, the attached parasites were counted.
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the number of infected cells (Figure 7A) and the number of amasti-
gotes per cell (Figure 7B).
Identiﬁcation of surface mucins as galectin ligands
on T. cruzi
Once it was shown that galectins bind to T. cruzi, attempts to identify
the galectin ligand on the parasite cell surface were carried out by
using biotin-labeled recombinant galectins. It was detected a diverse
array of protein bands ranging from 10 to 100 kDa, speciﬁc and vari-
able for individuals galectins. A discrete band ∼80–70 kDa was com-
mon for all galectins tested; however, the total number of proteins
detected was qualitatively different for each galectin (Figure 8A).
Gal-4 seemed to be the more restricted ligand galectin, with just the
band ∼80–70 kDa detected in the eluate, in contrast to gal-1 that
showed the most complex pattern of ligands. Interestingly, gal-7 and
-8 showed an almost identical pattern of ligands. To identify the para-
site proteins contained in the samples, identical membranes were sliced
and subjected to peptide mass ﬁngerprinting. The identiﬁed proteins
are shown in Table II. By using speciﬁc antibodies again parasite mu-
cins, the presence of the mucin AgC10 among the human gal-7 and -8
ligands was demonstrated (Figure 8B).
Unweighted pair-group median arithmetic analysis
As galectins are relevant factors in the outcome of immune responses,
we decided to test whether a differential galectin binding could be as-
sociated to different DTUs described for T. cruzi, since DTUs are also
associated to clinical manifestations. A similar binding pattern to dif-
ferent T. cruzi strains would indicate that inter-strain differences on
exposed glycans are not signiﬁcant and hence not being a discrimin-
atory element, or in contrast, showing strain speciﬁc galectin binding
(distinguishing speciﬁc traits like type of galactose containing glycans
exposed on the cell surface). In a similar fashion as the referenced
strain Y, intracellular amastigotes and CTT from the strains tested
(Table I) were the forms that showed the highest binding for all galec-
tins tested. Furthermore, some differences were found when the MFI
for each galectin-binding proﬁle was analyzed (shown in Tables III and
IV). Based on these differences, we decided to carry out an unweighted
pair-group median arithmetic (UPGMA) analysis of MFI values vs.
DTUs to identify whether there was a common pattern for strains be-
longing to the same lineage. The resulting dendrogram shows that the
14 strains were grouped in six clearly discrete clusters when CTTwere
analyzed (Figure 9A) and in ﬁve clusters when amastigotes were
utilized (Figure 9B) where the last cluster included strains from
DTUs IV and V.
Discussion
Speciﬁc interactions between galectins and glycoconjugates are consid-
ered to be critical determinants in pathogen recognition (Rabinovich
and Gruppi 2005; Vasta 2009; Paz et al. 2010). There is no direct evi-
dence whatsoever regarding different galectins binding to the three life
forms of this pathogen, and more important yet, there is no data on dif-
ferential interaction of innate immune components (c-type lectins, galec-
tins, etc.) to different parasite genetic lineages. Under this premise, we
Fig. 7. Galectin binding promotes productive infections. CTT (strain Y, DTU II) were incubated with LLC-MK2 cells for 15 min at 16°C in the presence or absence of
2 μM recombinant galectin, after extensive washing, the cells were incubated at 37°C for up to 5 days. At indicated times, cells were washed twice with PBS, ﬁxed
with Bouins ﬁxative solution and stained in Giemsa solution. The intracellular amastigotes were quantiﬁed by counting randomly at least 300 cells.
Fig. 8. Identiﬁcation of parasite galectin ligands. (A) CTT protein extracts were
applied to immobilized galectin columns, washed extensively and eluted with
100 mM lactose, resolved by SDS–PAGE, transferred to nitrocellulose
membranes and blotted with biotin-labeled recombinant galectins, and
revealed with streptavidin–HRP. (B) Either Gal-7-GST or Gal-8-GST was
immobilized to Glutation-Sepharose® and CTT extracts were applied. GST
immobilized was used as a control. After extensive washing, the column was
eluted with 100 mM lactose. Eluted fractions were subjected to western blot
using speciﬁc antibodies against T. cruzi mucin AgC10. 1: Gal-7-GST column
lactose elution, 2: Gal-8-GST column lactose elution, 3: GST column lactose
elution, 4: blank Sepharose lactose elution, 5, 6: washing elutions, 7: puriﬁed
AgC10.
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decided to ascertain whether different human galectins are able to spe-
ciﬁcally recognize glycans exposed on the cell surface of the three life
forms of the pathogenic parasite T. cruzi.
It is known that the parasite surface glycoconjugates are different
in every biological stage of the parasite (de_Lederkremer and Colli
1995; Ferguson 1997; Bourguignon et al. 1998; Colli and Alves
1999; de Lederkremer and Agusti 2009). Our results show that the
life forms present in the host (amastigotes and trypomastigotes) are re-
cognized to a greater extent than the non-infective epimastigotes, re-
ﬂecting the changes that take place in membrane composition,
accessibility and exposure of glycans on the infective forms, probably
related to the infective capacity.
Table II. Proteins from T. cruzi cell-derived trypomastigotes (strain Y) bound to galectins
Protein (MW) Sequence of identiﬁed peptide Accession number
Gal-1 Surface protease GP63 putative R.GRPVVGVINPR.H
R.NVGEVTGGEEPASPVTVSVGSDWAPLR.I
R.LLVRPLDGPLVVPR.F
R.SSVHVVNSR.N
R.FREGSVCGK.F
Q4CM87
GP90 K.AYTVLGPTDGTDNRVGFFYHPTTTTK.L
K.QSTIDAHEVK.L
K.LTESDSEVMWPVNTR.V
K.VFLLVGSLGELK.E
R.EPTDSEPTGGITWGEIK.S
AAM47176
GP82 R.GEIDAQYAVDGK.L
K.GNLDVVLSPTTTMK.G
R.KVMLYTQR.G
ABR19835
Mucin TcMUCII, putative K.MNVNSEGSNTQEDEEGGRNK.A EAN93978.1
Calcium-binding protein K.VEDPAALFK.E
K.LDEFTPR.V
BAA13411.1
Surface protein-1 K.APSESTPLLGAGLGDNDGTK.F AAB18265.1
Trans-sialidase, putative K.SLLGQIAPQAQGDSK.V
K.NFFLYNRPLSADELK.M
EAN98599.1
Gal-3 Surface protease GP63 putative R.LLVRPLDGPLVVPR.F
K.VDILENVILSEAAK.M
Q4CM87
GP90 K.AYTVLGPTDGTDNRVGFFYHPTTTTK.G
K.LTESDSEVMWPVNTR.V
K.TTESGTWEPGKEYQVAL.M
R.KVMLYTQR.G
R.EPTDSEPTGGITWGEIK.S
AAM47176
GP82 K.LVVGEVTKPSAGGEPSG.W
K.FTGFGSGAIWPVNNR.E
ABR19835
Trans-sialidase, putative K.SLLGQIAPQAQGDSK.V EAN98599.1
Gal-4 Surface protease GP63 putative R.LLVRPLDGPLVVPR.F
R.SSVHVVNSR.N
R.FREGSVCGK.F
R.NVGEVTGGEEPASPVTVSVGSDWAPLR.I
R.VAVHEM*AHALGFIVTDM*EGQALVK.R
K.VDILENVILSEAAK.M
Q4CM87
GP90 K.GELSSSLLYSDGNLQLLQQR.G
R.VGFFYHPTTTTK.G
K.SQSFFSDLK.L
R.EPTDSEPTGGITWGEIK.S
K.EDGENCLLSTGVSPAK.C
AAM47176
Gal-7 Surface protease GP63 putative K.VDILENVILSEAAK.M
R.LLVRPLDGPLVVPR.F
R.FREGSVCGK.F
Q4CM87
Mucin TcMUCII, putative K.MNVNSEGSNTQEDEEGGRNK.A EAN93978.1
Gal-8 Surface protease GP63 putative R.FREGSVCGK.F
R.LLVRPLDGPLVVPR.F
Q4CM87
GP90 R.KVMLYTQR.G
K.LTESDSEVMWPVNTR.V
K.AYTVLGPTDGTDNRVGFFYHPTTTtK.G
R.EPTDSEPTGGITWGEIK.S
AAM47176
GP82 K.NVFLYNPRPLGADELR.M
K.FTGFGSGAIWPVNNR.E
K.GNLDVVLSPTTTMK.G
ABR19835
Mucin TcMUCII, putative K.MNVNSEGSNTQEDEEGGRNK.A EAN93978.1
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The major glycoconjugates of T. cruzi, the mucins, are longer in the
trypomastigotes and contain additional α-galactopyranosyl residues
(Almeida et al. 1999; Buscaglia et al. 2006). Those changes are sup-
posed to allow adaptation and survival in a new environment, where
the parasite will encounter immune mechanisms controlled by immune
regulators, such as galectins.Whether the parasite evolved to display ga-
lectin ligands in the infective forms, or the host developed galectins with
greater afﬁnity towards infective form glycans is difﬁcult to predict over
the common evaluative pressure of both parts. In that context is worth
mentioning that mannose receptor and mannose-binding proteins have
been described to favor binding of amastigotes tomacrophages that had
not been activated by IFN-γ (Kahn et al. 1995).
We observe that intracellular amastigotes are the parasite form that
binds galectins with the highest afﬁnity. In that sense, it results inter-
esting that intracellular amastigotes are “coated” with the cytosolic
soluble galectin pool from infected cells. It has been described an
alternative infection cycle inside the host, where intracellular amasti-
gotes released from lysate cells may initiate a new round of infection by
attaching and then infecting neighbor cells. Besides altering the normal
functions of cytosolic galectins (by altering the intracellular pool) that
galectin coating of amastigotes could favor a fast entry into neighbor
cells by promoting adhesion and facilitating invasion with galectins
acting as bridge between cells and parasites. Another possibility for
the “decoration” with galectins would be to induce a receptor re-
arrangement of the galectin lattice at the host cell surface modiﬁcation
in that way the signaling pathways that allow the amastigote to survive
in the extracellular milieu before obligate transformation to trypomas-
tigotes or initiate a new invasion cycle or simply tagging the amasti-
gotes with a danger signal that favors the engulfment by
macrophages. Whether this “coating” or “recruiting” of intracellular
galectins confers to the parasite any advantage is just a matter of
speculation at the moment. Remarkably, recent ﬁndings showed a re-
cruitment of structures expressing gal-3 to vacuoles containingT. cruzi
amastigotes (Machado et al. 2014; Reignault et al. 2014), and some
reports showed that gal-3 covers intracellular Mycobacterium-
containing phagosomes promoting pathogen killing (Beatty et al.
2002). An intriguing alternative is that sequestering cytosolic gal-3
may impair the phagocytic capacity of already infected cells by redu-
cing actin cytoskeletal rearrangement (Sano et al. 2003). There are
several reports showing the ability of galectins to bind to pathogens,
such as viruses (Levroney et al. 2005; Ouellet et al. 2005), bacteria
(Barboni et al. 2005; Fowler et al. 2006), (Mey et al. 1996), Candida
sp. (Kohatsu et al. 2006) and the helminth Schistosoma mansoni (van
den Berg et al. 2004). In addition, gal-3 and -9 bind Leishmania major
(Pelletier and Sato 2002; Pelletier et al. 2003; van den Berg et al. 2004).
Regarding T. cruzi, only gal-3 has been described to interact with the
parasite (Moody et al. 2000; Kleshchenko et al. 2004) to promote
adhesion to coronary artery smooth muscle cells and to extracellular
matrix via a laminin bridge. Our data provide evidence that gal-3
binds T. cruzi amastigote surface, and for the ﬁrst time we provide evi-
dence that also other galectin members like gal-1, -4, -7 and -8 can
bind the parasite, preferentially amastigotes and CTT of all genetic
lineages of T. cruzi. Of note, galectin binding may render more
productive infections for the parasite protozoan. The relevance of
T. cruzi–galectin interaction might vary depending on the individual
galectin and on the cell type or matrix component that the parasite in-
teracts with. If that is the case, our data suggest that T. cruzi could use
different combinations of galectins to adhere and to infect cells in dif-
ferent tissues, perhaps reminiscent of the differential tropism exhibited
by different lineages.
Gal-7, located mainly on skin and stratiﬁed epithelia (Magnaldo
et al. 1995, 1998), is the only galectin that showed signiﬁcant binding
to the epimastigotes form. Epimastigotes are present on the vector and
despite some reports showing infectivity (Burger et al. 1982), they are
generally considered to be non-infective. The signiﬁcance of this might
be related to the presence of epimastigotes or metacyclic trypomasti-
gotes excreted in the feces (Schaub and Losch 1988). That opens the
possibility that gal-7, located at the point of parasite entry, such as the
skin, could have evolved to interact with parasite forms found there at
the moment of infection, before new infective forms arise in the host.
Using a classical approach of afﬁnity chromatography allowed us
to partially identify, by peptide mass ﬁngerprinting, a very limited and
restricted group of membrane proteins from CTT as ligands. Two pro-
teins were found to be recognized by all the human galectins tested, the
putative protease GP63, GP90. The GP82, a putative mucin (TcMU-
CII) and a putative transialidasewere also common ligand partners for
the human galectins tested in this study. Using an alternative approach
Table III. Median ﬂuorescence index (MFI) for each galectin-FITC
against CTT from the indicated strains
Strain DTU MFI
gal-1
MFI
gal-3
MFI
gal-4
MFI
gal-7
MFI
gal-8
Silvio/X10 c1 TcI 15 ± 3 48 ± 5 14 ± 4 48 ± 4 19 ± 4
Dm28c TcI 17 ± 4 47 ± 7 15 ± 5 51 ± 9 22 ± 5
Esmeraldo c3 TcII 15 ± 3 19 ± 4 16 ± 7 80 ± 6 30 ± 8
Y TcII 18 ± 4 15 ± 6 19 ± 5 77 ± 8 26 ± 6
Tu18 c2 TcII 17 ± 5 18 ± 4 21 ± 6 75 ± 8 28 ± 9
Cm17 TcIII 19 ± 3 38 ± 5 20 ± 5 55 ± 7 39 ± 7
M6241 c6 TcIII 22 ± 5 39 ± 7 24 ± 6 60 ± 10 41 ± 6
Can III TcIV 28 ± 7 38 ± 5 19 ± 7 65 ± 8 46 ± 7
10R26 TcIV 35 ± 7 37 ± 6 18 ± 8 57 ± 10 31 ± 8
Bug2148 c11 TcV 18 ± 5 40 ± 5 16 ± 7 68 ± 6 31 ± 3
Sc43 c1 TcV 19 ± 5 42 ± 3 19 ± 4 78 ± 7 32 ± 2
Tula c2 TcVI 20 ± 5 26 ± 6 21 ± 5 57 ± 5 21 ± 3
VFRA c1 TcVI 21 ± 4 28 ± 2 22 ± 8 49 ± 4 20 ± 3
CL-Brener TcVI 19 ± 3 27 ± 4 25 ± 4 55 ± 4 24 ± 3
Each ﬂow cytometry analysis was carried out three times and the
median ± SD is shown.
Table IV. Median ﬂuorescence index (MFI) for each galectin-FITC
against amastigotes from the indicated strains
Strain DTU MFI
gal-1
MFI
gal-3
MFI
gal-4
MFI
gal-7
MFI
gal-8
Silvio/X10 c1 TcI 19 ± 7 25 ± 4 91 ± 10 78 ± 8 47 ± 8
Dm28c TcI 27 ± 5 27 ± 6 87 ± 8 71 ± 7 41 ± 9
Esmeraldo c3 TcII 87 ± 5 29 ± 8 125 ± 10 79 ± 3 30 ± 8
Y TcII 78 ± 8 31 ± 5 94 ± 8 58 ± 9 21 ± 4
Tu18 c2 TcII 97 ± 7 35 ± 9 130 ± 12 75 ± 8 28 ± 9
Cm17 TcIII 45 ± 6 88 ± 43 150 ± 11 98 ± 8 61 ± 7
M6241 c6 TcIII 41 ± 8 97 ± 6 112 ± 9 87 ± 11 71 ± 8
Can III TcIV 39 ± 6 65 ± 7 75 ± 8 99 ± 7 44 ± 8
10R26 TcIV 45 ± 4 59 ± 8 85 ± 7 125 ± 15 43 ± 3
Bug2148 c11 TcV 54 ± 7 71 ± 2 67 ± 4 98 ± 3 41 ± 8
Sc43 c1 TcV 61 ± 3 81 ± 3 57 ± 9 108 ± 11 29 ± 7
Tula c2 TcVI 27 ± 4 52 ± 8 90 ± 4 57 ± 5 31 ± 5
VFRA c1 TcVI 32 ± 8 68 ± 3 81 ± 9 65 ± 3 40 ± 6
CL-Brener TcVI 39 ± 7 77 ± 9 78 ± 10 70 ± 7 38 ± 7
Each ﬂow cytometry analysis was carried out four times and the median ± SD
is shown.
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like western blot using soluble streptavidin-labeled galectins, in which
the multivalency of galectins is preserved, we could observe many
more unidentiﬁed ligands. A band ∼70–80 kDa was the main
T. cruzi trypomastigote ligand of all the galectins tested. We could
identify just one potential ligand of gal-3, -7 and -8 as the mucin
AgC10 (Kierszenbaum et al. 2002; Alcaide and Fresno 2004a,
2004b). Moody et al. (2000) showed a 45 kDa parasite mucin that
was detected as a gal-3 ligand that could be AgC10. Gal-3 could be
implicated in the immunosuppressor activities attributed to the
mucin, as is known that gal-3 modulates T cell responses by control
of TCR clustering at the immune synapse (Demetriou et al. 2001).
Other galectins might be concerned as it could bind to common recep-
tors (Patnaik et al. 2006), although the biological functions derived
from different transduction signals must not be necessarily the same.
As galectins are multivalent proteins, they can cross-link receptors
mediating cell–cell adhesion and/or cell–extracellular matrix. There-
fore, experiments were conducted to evaluate the ability of galectins
to promote parasite adhesion to host cells. The galectin-induced adhe-
sion was both concentration- and CRD-dependent. When gal-8 null
mutant was used, adhesion was abrogated, suggesting that an active
CRD is required to favor parasite adhesion to host cells. Nevertheless,
the gal-8 mutant that has a non-functional N-terminal domain,
gal-8R233, is still able to promote parasite adhesion to host cells, al-
though in a lesser extent than the wild type. Gal-8R233 is supposed
not to cross-link glycosylated receptors, as only one-terminal domain
of the protein keeps CRD. It could be argued that the mutated CRD
interacts with some host molecules in a sugar independent way. How-
ever, that is not occurring in the parasite binding because lactose inhi-
bits wild-type gal-8 binding to the parasite. Another explanation,
although gal-8 is a tandem repeat, is that the protein can form homo-
dimers through the N-terminal CRD, as it has been published before
(Stowell et al. 2008). In that way, gal-8 could still bind with relative
high afﬁnity to cognate ligands.
A way in which the galectin binding to the parasites could be
modiﬁed by altering the galectin ligands exposure, for example by
β-galactosidases or the sialyltransferase ST6 (Zhuo and Bellis 2011)
acting as negative regulators. It could be argued that the transialidase
(TS) from T. cruzi, considered a virulence factor, could act as such
modulator, but that is not the case as the TS does not transfer sialic
acids linked α2–6 (Vandekerckhove et al. 1992) and hence could
not modify the galectin binding to host self-ligands; however, there
are no reports of T. cruzi β-galactosidase as virulence factor.
By evaluating whether different reference strains with clearly
distinct biological behavior exhibit differential binding to host
immune proteins like galectins, support to the notion that speciﬁc
traits in the different genetic lineage or DTUs of T. cruzi could be as-
sociated to differential pathology is provided. If there is a differential
galectin-binding proﬁle for each genetic lineage that could mean that
different immune responses networks would be triggered at different
tissues and eventually be correlated to the differential course of the
Chagas’ disease pathology. This analysis allowed to build a tree
with six groups clearly deﬁned that closely resembles the one built
solely on genetic data.
A parallel analysis taking the similarity matrix build on amasti-
gote-galectin-binding proﬁle data arranged the different lineages in
ﬁve clusters containing each one a single DTU and a mixed cluster
containing DTUs IV and V together.
Our ﬁndings are compatible with the idea that DTUs II (arranged
in the tree far apart from the rest) and I are ancient parental lineages
and that DTUs IV and V are recent ones derived from at least one re-
combination event (one cluster together or very close). This is to our
best knowledge the ﬁrst report of clustering the DTUs based on bio-
logical properties.
A great limitation of UPGMA is that it assumes the same evolution-
ary speed on all lineages, i.e., the rate of mutations is constant over
time for all lineages in the tree, and sowe must be very cautious imply-
ing that the rate of changes in glycan modiﬁcations on each lineage is
constant and that the distances reﬂect true evolutionary distance. It is
clear that further studies including more strains and isolates is neces-
sary before any conclusions can be raised.
Fig. 9. UPGMA analysis of galectin-binding proﬁles. A matrix was built with the data shown in Tables III and IV, presenting the Median Fluorescence Index (MFI) for
the binding of each galectin to CTT (A) or amastigotes (B) of each parasite strain in order to construct a dendrogram reﬂecting relationships between the different
T. cruzi DTUs represented by the reference strains used in this study.
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The results also reﬂect changes in the composition and quantity
(ratio of enzymes involved in synthesis/modiﬁcation of glycans) of “gly-
cogenes” in the lineages genomes. It must be considered here that gly-
coconjugates are not direct products of the genome, but the result of a
series of variable sequences of “glycogenes” actions, and subtle changes
on them may result in a great diversity of structures, and for sure such
variations may have profound implications in virulence, antigenicity
and immune response deriving in variable pathogenesis (Varki 2011).
It is known thatT. cruzi lineages (Araujo et al. 2002), or different strains
showing dissimilar infectivity/virulence (Piazza et al. 1996) can be dis-
tinguished in vitro by their different afﬁnity towards PNA, suggesting
that different lineages exhibit different glycans on their surface. This
has been recently conﬁrmed by Soares et al. (2012) showing differential
expression of α-galactosyl residues in T. cruzi GPI-mucins, and by our
group showing differential glycan proﬁle by different strains of T. cruzi
(Bonay and Staudacher, in preparation).
The composition of lineages in a natural infecting population may
play a role in determining the outcome of the infection and may reﬂect
the differential interaction with host proteins regulating the immune
response. Providing evidence of discriminant reactivity of a family of
immune relevant proteins against different lineages imposes new views
on the causes and progression of the wide spectra of disorders asso-
ciated to the disease. In addition, it reinforces the notion that differen-
tial outcomes of T. cruzi infection could be inﬂuenced by the
complexity of the infecting T. cruzi population that interferes with
host factors related to regulation of acute inﬂammatory response
essential for protection against infection, but may also contribute to
pathology. This represents the ﬁrst step to extend this analysis to an-
other relevant protein in order to increase the view on how the innate
immune system perceives the different parasites/strains and thus
provides a clue to elaborate complex networks of interactions and de-
ciphers the ﬁne-tuning events occurring with complex pathogens.
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